Newsbenzinga
QUICK SPARK: This New ETF Goes Beyond Eli Lilly, Novo Nordisk and Targets the Peptide Boom
· Published
Article summary
REX launches the PEPT ETF, offering exposure beyond Eli Lilly and Novo Nordisk as the GLP-1 market heads toward $200 billion by 2030.
An excerpt from the original article.
Comments —
Loading comments…